Phase 3 N=485 Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
Prostate Cancer
Primary: Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group — 0.38; 0.45; 0.76; 0.73 proportion
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=30 Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye
Dry Eye · Sjogren Syndrome
Primary: Change From Baseline in Ocular Surface Staining — 1.2; 2.4 score on a scale
Phase 3 N=900 A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event (AE) — 47.5; 37.6; 38.8; 43.0 Percentage of Participants — p== 0.525
Phase 3 N=2,425 Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Diabetes Mellitus, Type 2 · Coronary Artery Disease
Primary: Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE — 34; 42; 76; 92 events — p=0.1070
Phase 3 N=19 This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding
Hemorrhage
Primary: Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time — 100.0; 100.0; 100.0 Percentage
Phase 3 N=75 Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
Primary Immunodeficiency
Primary: Annual Rate of Occurrence of Serious Bacterial Infections (SBI) — 0; 0.01; 0; 0.03 Rate of events per subject per year
Phase 3 N=35 Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
Primary: Number of Patients Who Complete Planned Oncologic Therapy Without the Development of a Hematological Event — 35 Participants
Phase 3 N=275 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
Non-small Cell Lung Cancer · Lung Cancer · Advanced Malignancies
Primary: Progression-free Survival (PFS) — 24.016; 11.072; 16.821 months — p=<0.0001
Phase 3 N=609 Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
Gastroesophageal Reflux Disease (GERD)
Primary: Change From Baseline in WHSS at Week 8 — -1.751; -1.814 score on a scale — p=0.5566
Phase 3 N=175 A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
Cystic Fibrosis
Primary: Absolute Change in CF Questionnaire-Revised (CFQ-R) Respiratory Domain Score — 1.2; 17.1 units on a scale — p=< 0.0001
Phase 3 N=20,099 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
Healthy Volunteers
Primary: Vaccine Efficacy (VE) of Two Doses of Tetravalent Dengue Vaccine Candidate (TDV) in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype — 149…
Phase 3 N=26 Benralizumab for Eosinophilic Gastritis (BEGS)
Eosinophilic Gastritis or Gastroenteritis
Primary: Percent of Patients in Histological Remission (<30 Eos/Hpf) — 77; 8 percentage of participants — p=0.0001
Phase 3 N=153 Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration
Management of Chronic Pain
Primary: Proportion of Subjects Who Are Treatment Failures During the Double-blind Randomized Withdrawal Period — 18; 24 Participants — p=0.147
Phase 3 N=75 Study of Octanorm Subcutaneous IG in Patients With PID
Primary Immune Deficiency Disorder
Primary: Rate of SBI Per Person-year — 0 SBIs per person year
Phase 3 N=30 Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
Advanced Cancer
Primary: Mean Nausea Scores — 1; 9 units on a scale